Original language | English |
---|---|
Pages (from-to) | 58-61 |
Number of pages | 4 |
Journal | Thrombosis Research |
Volume | 184 |
DOIs | |
State | Published - Dec 2019 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Thrombosis Research, Vol. 184, 12.2019, p. 58-61.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients
T2 - A systematic review and meta-analysis
AU - Chiasakul, Thita
AU - Evans, Christina R.
AU - Spyropoulos, Alex C.
AU - Raskob, Gary
AU - Crowther, Mark
AU - Cuker, Adam
N1 - Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion , Bayer , Novo Nordisk , Pfizer , Sanofi , Spark , and Takeda . A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen , Boehringer Ingelheim , and BMS/Pfizer . G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation , and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures. Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion, Bayer, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen, Boehringer Ingelheim, and BMS/Pfizer. G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation, and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures.
PY - 2019/12
Y1 - 2019/12
UR - http://www.scopus.com/inward/record.url?scp=85074504958&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2019.10.027
DO - 10.1016/j.thromres.2019.10.027
M3 - Letter
C2 - 31707152
AN - SCOPUS:85074504958
SN - 0049-3848
VL - 184
SP - 58
EP - 61
JO - Thrombosis Research
JF - Thrombosis Research
ER -